Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16; 294(19):2446-54.

View in: PubMed

subject areas

Aged
Angiography
Coronary Artery Bypass
DNA
Double-Blind Method
E2F Transcription Factors
Female
Genetic Therapy
Graft Occlusion, Vascular
Humans
Hyperplasia
Male
Middle Aged
Oligonucleotides
Saphenous Vein
Survival Analysis
Tissue and Organ Harvesting
Transfection
Transplantation, Autologous
Transplants
Vascular Patency

authors with profiles

Robert Harrington